Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2023 | Using whole genome sequencing to identify novel predictors for SCT in patients with MDS

Wael Saber • 21 Oct 2023
COSTEM 2023
Myelodysplastic Syndromes

Wael Saber, MD, MS, Froedtert & Medical College of Wisconsin, Milwaukee, WI, discusses a recent publication which explored the use of whole genome sequencing (WGS) to identify novel prognostic factors to predict the outcomes of patients with myelodysplastic syndromes (MDS) undergoing stem cell transplantation (SCT). This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wael Saber

1:40
Unrelated younger donors vs older sibling donors when transplanting patients with MDS & AML
Wael Saber • 21 Oct 2023
1:13
Selecting conditioning regimens for patients with myelofibrosis undergoing alloSCT
Wael Saber • 21 Oct 2023
1:40
How donor age impacts outcomes in patients with AML undergoing alloSCT
Wael Saber • 21 Oct 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals